Gastrointestinal Cancers
NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers, Version 2.2023
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers, Version 2.2023
AACR 2023: Does Pembrolizumab Improve Outcomes in Biliary Tract Cancer?
Rapid Changes in Colorectal Cancer Statistics: American Cancer Society Report
ASCO GI 2023: NAPOLI-3 Trial in Metastatic Pancreatic Ductal Adenocarcinoma
ASCO GI 2023: Zolbetuximab Plus mFOLFOX6 For Certain Patients With Advanced Gastric Cancers
Safety and Efficacy of Sotorasib in KRAS-Mutated Pancreatic Cancer
Consumption of Ultraprocessed Foods and Colorectal Cancer Risk
Consumption of Sugar-Sweetened Beverages and Risk of Liver Cancer
ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
ASCO 2022: Nimotuzumab Plus Gemcitabine for KRAS Wild-Type Pancreatic Cancer
ASCO 2022: Panitumumab Plus mFOLFOX6 for Certain Patients With Metastatic Colorectal Cancer
ASCO 2022: Using ctDNA to Guide Adjuvant Chemotherapy in Colon Cancer
MSI-H/dMMR Advanced Colorectal Cancer: Pembrolizumab vs Chemotherapy
Pembrolizumab/Trametinib vs Gemcitabine in Addition to SBRT for Pancreatic Cancer
Immunotherapy Doublet in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
Combination Anti–PD-L1 and Anti–CTLA-4 Immunotherapy in Advanced Liver Cancer
TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Treatment Options for Patients With GIST Following Disease Progression